Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.44 |
| ▸ | HTR2C | P28335 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97861 | 0.84 | PSEN1 (0.41) | IDO1AGXTDAO | |
| SCHEMBL28052426 | 0.82 | CA3 (0.43) | IDO1AGXT | |
| SCHEMBL30515548 | 0.81 | ALDH1A1 (0.43) | KDM4ESMN1; SMN2 | |
| SCHEMBL2145125 | 0.81 | PDPK1 (0.48) | — | |
| SCHEMBL17713505 | 0.81 | PKM (0.37) | IDO1AGXTDAOHTR2ASMN1; SMN2 | |
| SCHEMBL20399857 | 0.81 | ALDH1A1 (0.43) | KDM4ESMN1; SMN2 | |
| SCHEMBL7700904 | 0.80 | IDO1 (0.58) | IDO1AGXTDAOHTR2AHTR2C | |
| SCHEMBL434184 | 0.80 | IDO1 (0.50) | IDO1AGXTDAOHTR2AHTR2C | |
| SCHEMBL13376689 | 0.80 | IDO1 (0.50) | IDO1AGXTDAOHTR2AHTR2C | |
| Methane SCHEMBL28277247 | 0.79 | TRPV4 (0.35) | IDO1AGXTDAOHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| CN-109983000-A | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | 拜耳作物科学股份公司 | 2019-07-05 | — | — | CN | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| CN-109134431-A | Aminooimidazole as cystic fibrosis transmembrane conductance regulator inhibitor is coupled Pyridione derivatives | 成都理工大学 | 2019-01-04 | — | — | CN | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| CN-104876955-B | Arginase inhibitor and its treatment use | 马尔斯公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| EP-0844993-A2 | PESTICIDAL INDAZOLE DERIVATIVES | Novartis AG (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0783888-A1 | Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis | SANKYO COMPANY LIMITED (JP) | 1997-07-16 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1997007103-A2 | PESTICIDAL INDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | IDO1 260/4885AGXT 128/4885DAO 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.